Saturday, February 4, 2012

Dr. Reddy Receives USFDA tentative approval for Requip XL

Yesterday, USFDA gave a tentative approval to Dr. Reddy for launching generic copies of Requip XL. Requip XL has global sales of about $250m, and the basic patent around it has expired, while the formulation patent expires in 2012 (June). Should be meaningful opportunity as there are not many players pursuing this. Torrent is likely the other Indian player. Reddy has an FTF on this. One of the orange book listed patent will expire in 2021, but it is unlikely to be a hurdle.